Skip to content

Definium Therapeutics, Inc.

DFTX

CIK 0001813814

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$210.46M
−69.1% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$2.34
−33.8% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
—
Q1 Apr 2026
Cash
$262.52M
Q1 Apr 2026
Total Debt
$40.77M
Q1 Apr 2026
Shares Outstanding
109.07M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings